Recipharm makes strategic appointment in the UK & Ireland

- May 26, 2017 - Recipharm, the contract development and manufacturing organisation (CDMO), has invested in its UK & Ireland presence with the appointment of Shabbir Mostafa to its Business Management team. 

Shabbir will join the Sweden-headquartered CDMO as Director, Business Management UK & Ireland with responsibility for supporting customers in the UK & Ireland and driving sales of Recipharm’s manufacturing services.

Commenting on the appointment, Kenth Berg, Vice President Business Management at Recipharm said: “The UK & Ireland continues to be an important market for Recipharm as we expand our localised presence throughout Europe. Our vision is to be recognised as the best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry and in order to achieve this, we are focused on attracting and recruiting excellent people.”

“As we continue to grow as a company, with our focus on decentralised operations, we are highly dependent on talented people at key posts throughout the Recipharm organisation. With his extensive knowledge of the pharmaceutical sector in the UK & Ireland, we believe Shabbir is the perfect addition to our team and will help to drive our business forward in this key market.”

With a PhD in Pharmaceutical Sciences, Shabbir joins Recipharm from Aesica Pharmaceuticals where he was the Business Development Director with responsibility for global formulation development services and the commercial finished dose business in the UK & Ireland. During his 15 year career, he has also held positions at PCI Pharma Services, Gattefossé, Patheon and IVAX Pharmaceuticals.

Shabbir said: “Recipharm is highly regarded as a significant force in the pharmaceutical sector and as the CDMO continues to expand its presence and service offering globally, it’s an exciting time to join the team. Recipharm is focused on simplifying the supply chain and managing complexity on behalf of pharmaceutical companies across the world and I look forward to playing my part by supporting our customers in the UK & Ireland.”

Contact information
Kenth Berg, VP Business Management, kenth.berg@recipharm.com, +46 8 6025 216

For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com, + 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /remarketing 

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com